Delisting riskPopularity #3,841
SLXN · NASDAQ · Biotechnology

Silexion Therapeutics (SLXN)

Develops RNA-targeting treatment candidates for KRAS-mutated pancreatic cancer.

$0.4700
vs last close−0.07 (−13.62%)